Health Care • Medicinal Chemicals and Botanical Products
$2.50 ▼ -0.04
(-1.57%)
MKT CAP: $197.8M • VOL: 348.4K
52W L $2 52W H $8
NAGE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $129.4M | $99.6M | $83.6M |
| YoY Revenue Growth % | +29.9% | +19.2% | — |
| Gross Profit | $83.2M | $61.6M | — |
| Gross Margin % | 64.3% | 61.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $16.3M | $7.7M | -$5.6M |
| Operating Margin % | 12.6% | 7.8% | -6.7% |
| Net Income (GAAP) | $17.4M | $8.6M | -$4.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $13.5M | $12.1M | $7.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $13.5M | $12.1M | $7.1M |
| FCF Margin % | 10.4% | 12.2% | 8.5% |
| Return on Invested Capital (ROIC %) | 16.8% | 95.0% | — |
| Cash & Short-Term Equivalents | — | $44.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $76.5M | $46.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NAGE.